Allogene Therapeutics Inc
(NAS:ALLO)
$
2.125
+0.020 (+0.95%)
Market Cap: 733.45 Mil
Enterprise Value: 537.48 Mil
PE Ratio: 0
PB Ratio: 1.86
GF Score: 32/100 Allogene Therapeutics Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 15, 2021 / 06:30PM GMT
Release Date Price:
$25.03
(-1.34%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
All right. Good day, everybody. Thank you for joining us at the BofA Biotech Summit. It's typically held in Napa. Unfortunately, we're in front of computer screens, but I think there's an end in sight that -- to a future that can be held with some red wine in the evenings. But gentlemen -- and I'm pleased -- I'm Jason Gerberry, biotech -- one of the biotech analysts at BofA. I'm pleased to be introducing Allogene CEO, David Chang; and CFO, Eric Schmidt. And gentlemen, thanks so much for joining us, first off.
Eric Thomas Schmidt
Allogene Therapeutics, Inc. - CFO
Thank you, Jason.
David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director
Jason, thank you very much for having us. And as you say -- I mean today is June 15, so things are opening up. So pretty soon, hopefully, we will be back to normal.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot